3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myeloid, Acute
3
Leukemia
3
Vomiting
2
Stomach Neoplasms
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Motor Activity
2
Ventilator-Induced Lung Injury
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Substance-Related Disorders
1
Solid Tumors
1
Recurrence
1
Postoperative Complications
1
Pancreatic Neoplasms
1
Opioid-Related Disorders
1
Opioid-Induced Constipation
1
Neurofibromatosis 1
1
Neoplasms
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Low Anterior Resection Syndrome
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
5
padeliporfin
5
Nivolumab
5
fludarabine
4
aldesleukin
4
Ipilimumab
4
Cyclophosphamide
4
atezolizumab
3
Specimen Handling
3
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Carboplatin
3
vedolizumab
2
olaparib
2
niraparib
2
motexafin gadolinium
2
cabozantinib
2
anlotinib
2
abiraterone
2
Therapeutics
2
Sunitinib
2
Standard of Care
2
Riluzole
2
Radiation Dose Hypofractionation
2
Prednisone
2
Pluvicto
2
Mitomycin
2
LDP-02
2
Infliximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urogenital Neoplasms
×
Dosage Forms
×
Clear all
NCT04644432
2020-11-25
INDIGO
Herlev and Gentofte Hospital
Phase 2
Unknown
30 enrolled